Bronchial asthma, COPD
Conditions
Interventions
None listed
Sponsors
Nagoya City University Hospital Allergy and Clinical Immunology
Toyokawa City Hospital, Asahi Rosai Hospital, Shizuoka Prefectural General Hospital, Teikyo University Hospital, Meijo Hospital, Kyoto Katsura Hospital, Gunma University Hospital, Toshiwakai Medical Center Le Clinic, Kasai Yokoyama Internal Medicine/Respiratory Medicine Clinic, Gamagori City Hospital, Keio University Hospital,Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Patients who are visiting or are visiting for the first time at the Outpatient Department of Asthma and Chronic Cough at Nagoya City University or the Outpatient Department of Respiratory Medicine at the above joint research institute hospital. 2 Patients with asthma or COPD. 3 Patients who have received at least 1 dose of COVID-19 vaccine from December 2021. 4 Patients who have given written informed consent to participate in this study
Exclusion criteria
Exclusion criteria: 1 Patients with other obvious respiratory diseases such as lung cancer, interstitial lung disease (excluding bronchiectasis). 2 Patients who are judged to be unsuitable as subjects by the investigator (co-investigator).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To elucidate the background factors and asthma/COPD phenotypes of patients who are prone to exacerbation of asthma/COPD triggered by COVID-19 vaccination. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Identify biomarkers associated with exacerbation of asthma and COPD by COVID-19 vaccination. 2. To assess whether COVID-19 vaccination is a risk factor for exacerbation of asthma/COPD. 3. To examine the feasibility of COVID-19 revaccination by examining the outcome of exacerbated cases with COVID-19 vaccination | — |
Countries
Japan
Contacts
Public ContactYoshihiro Kanemitsu
Nagoya City University Hospital Clinical Research Development Support Center
Outcome results
None listed